A comparative study on effectiveness of acceptance and commitment therapy and logotherapy on symptoms of depression, anxiety and stress of women suffering relapsing remitting multiple sclerosis: A randomized controlled trial study

References

• 1.
  Carlos Albuquerque, et al. Quality of life of people with multiple sclerosis: Clinical and psychosocial determinants / Procedia. Soc Behav Sci 2015; 171: 359-365.
• 2.
  Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg 2010; 112: 365-385.
• 3.
  Pak F, Nafariyeh T, Asghari N, Shokrollahy M, Kokhaei P. Immunopathology of multiple sclerosis. Koomesh 2013; 14: 117-129. (Persian).
• 4.
  Bruce S, Rabin M. Can stress participate in pathogenesis of auto immune disease? JAH 2002; 30: 71-75.
• 5.
  Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord 2016; 5: 12-26.##.
• 6.
  Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol 2014; 10: 507-517.
• 7.
  Motaharinezhad F, parvaneh S, bakhtiary AH, alizadeh N, ghahari S. The effect of mood and cognition on relationship between sleep disturbances and fatigue in people with multiple sclerosis. Koomesh 2016; 17: 613-619. (Persian).
• 8.
  Boeschoten RE, Braamse AM, Beekman AT, Cuijpers P3, van Oppen P, Dekker J, Uitdehaag BMJ. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 2017; 372: 331-341.
• 9.
  Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9-90.##.
• 10.
  Kalron A, Aloni R. Contrasting relationship between depression, quantitative gait characteristics and self-report walking difficulties in people with multiple sclerosis. Mult Scler Relat Disord 2018; 19: 1-5.
• 11.
  Motl RW, Balto J, Ensari I, Hubbard E, Self-efficacy and walking performance in persons with multiple sclerosis. J Neurol Phys Ther 2017; 41: 114-118.
• 12.
  Ensari I, Adamson BC, Motl RW. Longitudinal association between depressive symptoms and walking impairment in people with relapsing-remitting multiple sclerosis. J Health Psychol 2015; 1-10.
• 13.
  Fricska-Nagy Z, Fvesi J, Rzsa C, Komoly S, Jakab G, Cspny T, et al. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated. Mult Scler Relat Disord 2016; 7: 26-32.
• 14.
  Lublin FD, Reingold SC. "Defining the clinical course of multiple sclerosis: results of an international survey". Neurology 1996; 46: 907-911.
• 15.
  Beiske A, Svensson E, Sandanger I, Czujko B, Pedersen E, Aarseth J, et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008; 15: 239-245.
• 16.
  Dehghan A, Memarian R. Abundance of Stress, Anxiety and Depression in Multiple Sclerosis Patients. AUMJ 2013; 2: 82-88. (Persian).
• 17.
  Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A. Self-assessed health status changes in a community cohort of people with multiple sclerosis: 11 years of follow-up. Eur J Neurol 2013; 20: 681-688.
• 18.
  Percy CA, Gibbs T, Potter L, Boardman S. Nurse-led peer support group: experiences of women with polycystic ovary syndrome. J Adv Nurs 2009; 65: 2046-2055.
• 19.
  Noonan CW, Williamson DM, Henry JP, Indian R, Lynch SG, Neuberger JS, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010; 7: A12.
• 20.
  Hansen M. Cancer nursing. Principles and practice 2000; 5th ed. London.
• 21.
  Mardani M, Ghafari Z. The effectiveness of logotherapy on quality of life among MS patients in Shahrekord. SJIMU 2015; 23: 47-56. (Persian).
• 22.
  Robatmaili S, Honarmand MM, Zargar Y, Karimi R. The effect of group logotherapy on depression and hope in university students. Knowledge Res Appl Psychol 2013; 14: 3-10.
• 23.
  Rajabi S. M.A. Yazdkhasti F. The effectiveness of acceptance and commitment group therapy on anxiety and depression in women with MS who were referred to the MS association. J Clin Psychol 2014; 1: 29-38. (Persian).
• 24.
  Canter JW, Baruch DE, Gaynor ST. Acceptance and commitment therapy and behavioral activation for the treatment of depression: description and comparison. Behav Anal 2006; 29: 161-185.
• 25.
  Hallis L, Cameli L, Dionne F, Knuper B. Combining cognitive therapy with acceptance and commitment therapy for depression: a manualized group therapy. J Psychother Integrat 2016; 26: 186.
• 26.
  Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the beck depression and anxiety inventories. Behav Res Ther 1995; 33: 335-343.
• 27.
  Sahebi A, Asghari MJ, Salari RS. Validation of depression anxiety and stress scale (DASS-21) developmental pscychology. 1384; 4: 299-312 (Persian).
• 28.
  Afzali A, Delavar A, Borjali A, Mirzamani M. Psychometric properties of DASS-42 as assessed in a of Kermanshah highschool students. J Res Behav Sci 2007; 5: 81-92. (Persian).
• 29.
  Gall M, Walter R, Borg, Goyee P, Gall NY. Education research: an introduction; longman Publishers USA, c1996, 6th Ed.
• 30.
  Zamani E, Moatamedy A, Bakhtiari M. The effectiveness of acceptance and commitment group Therapy on anxiety in multiple sclerosis. Health Psychol 2017; 5: 152-167. (Persian).
• 31.
  Ghara Zibaei F, Aliakbari Dehkordi M, Alipour A, Mohtashami T. Efficacy of group logo therapy in the perceived stress and life expectancy in MS patients. RPH 2013; 6: 12-20. (Persian).
• 32.
  Kang K, Jea IM, Heesu K, Shingjeang K, MiKyung S, Sonyong S. The effect of logotherapy on the suffering, finding meaning, and spiritual well being of adolescents with terminal cancer. J Curr Direc Psychol Sci 2009; 42: 312.
• 33.
  Amir F, Ahadi H, Hatamian H, Nikkhah K, Seirafi M. The effectiveness of acceptance and commitment group therapy and group logotherapy in reducing perceived stress among MS patients. Caspian J Neurol Sci 2017; 3: 175-184.
• 34.
  Ghorbanalipoor M, Moghadamzadeh A, Jafari E. The effectivness of schema therapy and logo therapy on death anxiety in patients with hypochonderiasis. J Res Clin Psychol Counsel 2017; 7: 52-66. (Persian).
• 35.
  Mohammadizadeh A, Askarizadeh G, Bagheri M. The relationship between spiritual health and death anxiety in patients with multiple sclerosis. JRH 2017; 4: 20-28. (Persian).
• 36.
  Wood B, Van Der Mei IA, Ponsonby AL, Pittas F, Quinn S, Dwyer T, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler 2013; 19: 217-224.
• 37.
  Hosseinzadeh-Khezri R, Rahbarian M, Sarichloo ME, Lankarani KB, Jahanihashemi H, Rezaee F. Evaluation effect of Logotherapy group on Mental health and hope to life of patients with colorectal cancer receiving chemotherapy. Bull Env Pharmacol Life Sci 2014; 3: 164-169.
• 38.
  Eilenberg T, Fink P, Jensen JS, Rief W, Frostholm L. Acceptance and commitment group therapy (ACT-G) for health anxiety: a randomized controlled trial. Psychol Med 2016; 46: 103-115.
• 39.
  Twohig MP, Levin ME. Acceptance and commitment therapy as a treatment for anxiety and depression: A review. Psychiatr Clin North Am 2017; 40: 751-770.##.
• 40.
  Davison TE, Eppingstall B, Runci S, O'Connor DW. A pilot trial of acceptance and commitment therapy for symptoms of depression and anxiety in older adults residing in long-term care facilities. Aging Ment Health 2017; 21: 766-773.
• 41.
  Ruiz FJ, Odriozola-Gonzlez P. A longitudinal comparison of metacognitive therapy and acceptance and commitment therapy models of anxiety disorders. Anal Psicol Ann Psychol 2016; 33: 7-17.